EMIT-AF/VTE: Edoxaban management in diagnostic and therapeutic procedures
- Conditions
- ATRIAL FIBRILLATIONdeep vein thrombosispulmonary embolism
- Registration Number
- DRKS00010926
- Lead Sponsor
- Daiichi Sankyo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 1464
Inclusion Criteria
• Patients taking edoxaban for a therapeutic indication according to the SmPC (NVAF, VTE including DVT and PE)
• Paients with a planned or unplanned diagnostic or interventional procedure
• Age = 18 years
• Written informed consent
• Availability of patients for follow-up by telephone
• No concurrent participation in an interventional study
Exclusion Criteria
N/A
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Any bleeding event the patient experiences within 30 days of the procedure will be collected. This will be done by a phone call. The bleeding events are categorised according to ISTH (International Society on Thrombosis and Haemostasis) standards.
- Secondary Outcome Measures
Name Time Method Any cardiovascular event the patient experiences within 30 days of the procedure will be collected. This will be done by a follow up phone call to the patient.